What can we learn from molecular dynamics simulations for GPCR drug design?

Recent years have seen a tremendous progress in the elucidation of experimental structural information for G-protein coupled receptors (GPCRs). Although for the vast majority of pharmaceutically relevant GPCRs structural information is still accessible only by homology models the steadily increasing...

Full description

Bibliographic Details
Main Authors: Christofer S. Tautermann, Daniel Seeliger, Jan M. Kriegl
Format: Article
Language:English
Published: Elsevier 2015-01-01
Series:Computational and Structural Biotechnology Journal
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S200103701400052X
id doaj-99b301ba997646b79097adbda8dda7d0
record_format Article
spelling doaj-99b301ba997646b79097adbda8dda7d02020-11-24T20:59:07ZengElsevierComputational and Structural Biotechnology Journal2001-03702015-01-0113C11112110.1016/j.csbj.2014.12.002What can we learn from molecular dynamics simulations for GPCR drug design?Christofer S. TautermannDaniel SeeligerJan M. KrieglRecent years have seen a tremendous progress in the elucidation of experimental structural information for G-protein coupled receptors (GPCRs). Although for the vast majority of pharmaceutically relevant GPCRs structural information is still accessible only by homology models the steadily increasing amount of structural information fosters the application of structure-based drug design tools for this important class of drug targets. In this article we focus on the application of molecular dynamics (MD) simulations in GPCR drug discovery programs. Typical application scenarios of MD simulations and their scope and limitations will be described on the basis of two selected case studies, namely the binding of small molecule antagonists to the human CC chemokine receptor 3 (CCR3) and a detailed investigation of the interplay between receptor dynamics and solvation for the binding of small molecules to the human muscarinic acetylcholine receptor 3 (hM3R).http://www.sciencedirect.com/science/article/pii/S200103701400052XMolecular dynamics simulationsGPCRHomology modelingWater networkCC chemokine receptor 3Muscarinic acetylcholine receptor 3
collection DOAJ
language English
format Article
sources DOAJ
author Christofer S. Tautermann
Daniel Seeliger
Jan M. Kriegl
spellingShingle Christofer S. Tautermann
Daniel Seeliger
Jan M. Kriegl
What can we learn from molecular dynamics simulations for GPCR drug design?
Computational and Structural Biotechnology Journal
Molecular dynamics simulations
GPCR
Homology modeling
Water network
CC chemokine receptor 3
Muscarinic acetylcholine receptor 3
author_facet Christofer S. Tautermann
Daniel Seeliger
Jan M. Kriegl
author_sort Christofer S. Tautermann
title What can we learn from molecular dynamics simulations for GPCR drug design?
title_short What can we learn from molecular dynamics simulations for GPCR drug design?
title_full What can we learn from molecular dynamics simulations for GPCR drug design?
title_fullStr What can we learn from molecular dynamics simulations for GPCR drug design?
title_full_unstemmed What can we learn from molecular dynamics simulations for GPCR drug design?
title_sort what can we learn from molecular dynamics simulations for gpcr drug design?
publisher Elsevier
series Computational and Structural Biotechnology Journal
issn 2001-0370
publishDate 2015-01-01
description Recent years have seen a tremendous progress in the elucidation of experimental structural information for G-protein coupled receptors (GPCRs). Although for the vast majority of pharmaceutically relevant GPCRs structural information is still accessible only by homology models the steadily increasing amount of structural information fosters the application of structure-based drug design tools for this important class of drug targets. In this article we focus on the application of molecular dynamics (MD) simulations in GPCR drug discovery programs. Typical application scenarios of MD simulations and their scope and limitations will be described on the basis of two selected case studies, namely the binding of small molecule antagonists to the human CC chemokine receptor 3 (CCR3) and a detailed investigation of the interplay between receptor dynamics and solvation for the binding of small molecules to the human muscarinic acetylcholine receptor 3 (hM3R).
topic Molecular dynamics simulations
GPCR
Homology modeling
Water network
CC chemokine receptor 3
Muscarinic acetylcholine receptor 3
url http://www.sciencedirect.com/science/article/pii/S200103701400052X
work_keys_str_mv AT christoferstautermann whatcanwelearnfrommoleculardynamicssimulationsforgpcrdrugdesign
AT danielseeliger whatcanwelearnfrommoleculardynamicssimulationsforgpcrdrugdesign
AT janmkriegl whatcanwelearnfrommoleculardynamicssimulationsforgpcrdrugdesign
_version_ 1716783739009236992